Eli Lilly's stock price has surged 489.83% since 2020, reflecting a wave of successful product approvals and a strong market capitalization boost to $740 billion.
While some analysts base future stock price predictions on past growth rates, 24/7 Wall Street emphasizes assessing projected revenues and net income for accurate forecasts.
The recent FDA approvals for Eli Lilly's drugs, including Zepbound for obstructive sleep apnea and Kinsula for Alzheimer's, are pivotal in driving future value and growth.
Given Eli Lilly's expanding portfolio and successful market strategies, the next 3 to 5 years are crucial for determining its continued stock performance.
Collection
[
|
...
]